The agency told Bayer it needs additional time to review the non-hormonal drug, called elinzanetant. Regulators in Canada and ...

There is bipartisan consensus that drugs in the U.S. cost a lot more than in other high-income countries; therefore, it is important to comprehend how governmental interventions in other nations can ...

The U.S. Food and Drug Administration has extended its review of Bayer's experimental menopause relief drug, the German company said on Friday.